These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 29788127)

  • 1. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
    Colombel JF
    Inflamm Bowel Dis; 2018 Sep; 24(10):2173-2182. PubMed ID: 29788127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
    Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination.
    Galloway J; Raine T; Rivett L; Roberts J; Dews SA; Choy EH
    Clin Exp Rheumatol; 2022 Jul; 40(7):1432-1441. PubMed ID: 34874825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
    Bing N; Zhou H; Chen X; Hirose T; Kochi Y; Tsuchida Y; Ishigaki K; Sumitomo S; Fujio K; Zhang B; Valdez H; Vincent MS; Martin D; Clark JD
    Arthritis Rheumatol; 2021 Jul; 73(7):1155-1166. PubMed ID: 33455090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and safety of tofacitinib in ulcerative colitis.
    López-Sanromán A; Esplugues JV; Domènech E
    Gastroenterol Hepatol; 2021 Jan; 44(1):39-48. PubMed ID: 32829958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
    Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective.
    Caldera F; Hayney MS; Cross RK
    Inflamm Bowel Dis; 2019 May; 25(6):955-957. PubMed ID: 30605536
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
    Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
    Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
    Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
    Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
    Panés J; D'Haens GR; Sands BE; Ng SC; Lawendy N; Kulisek N; Guo X; Wu J; Vranic I; Panaccione R; Vermeire S
    United European Gastroenterol J; 2024 Jul; 12(6):793-801. PubMed ID: 38778549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C
    J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.
    Gialouri CG; Moustafa S; Thomas K; Hadziyannis E; Vassilopoulos D
    Rheumatol Int; 2023 Mar; 43(3):421-435. PubMed ID: 36635577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis].
    Yamaoka K
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):181-9. PubMed ID: 27320933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib for the treatment of ulcerative colitis.
    Izzo R; Bevivino G; Monteleone G
    Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
    Lopes SR; Martins C; Teixeira M; Tomás D
    World J Gastroenterol; 2024 Sep; 30(34):3929-3931. PubMed ID: 39350781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
    Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
    Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.